Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15556814 | 0.95 | CHRM2 (0.42) | CYP1A2MAPK1CHRM2TDP1CA12 | |
| SCHEMBL9460351 | 0.95 | CHRM2 (0.42) | CYP1A2MAPK1CHRM2TDP1CA12 | |
| SCHEMBL3459171 | 0.95 | CYP1A2 (0.37) | CYP1A2MAPK1CHRM2TDP1CYP2C9 | |
| SCHEMBL23742395 | 0.93 | CYP1A2 (0.33) | CYP1A2MAPK1CHRM2TDP1 | |
| SCHEMBL11212686 | 0.89 | MAPT (0.33) | CYP1A2MAPK1TDP1CA12CA1 | |
| SCHEMBL16925628 | 0.89 | DNM1 (0.42) | CHRM2 | |
| SCHEMBL3462018 | 0.87 | CHRM2 (0.44) | CYP1A2MAPK1CHRM2TDP1CA12 | |
| SCHEMBL3796629 | 0.85 | CHRM2 (0.48) | CYP1A2MAPK1CHRM2CA12CA1 | |
| SCHEMBL22482652 | 0.85 | LCK (0.40) | CYP1A2MAPK1CHRM2CYP2C9CYP2C19 | |
| SCHEMBL1492443 | 0.85 | CHRM2 (0.48) | CYP1A2MAPK1CHRM2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3713983-B1 | POLYURETHANE-BASED COMPOSITION | BOSTIK SA (FR) | 2021-05-19 | — | — | EP | disclosed |
| EP-3484973-B1 | ADHESIVE DUAL-COMPONENT COMPOSITION BASED ON POLYURETHANE | BOSTIK SA (FR) | 2020-12-23 | — | — | EP | disclosed |
| US-9439433-B2 | Compositions and methods comprising a biocidal polyamine | CURZA GLOBAL, LLC (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150038512-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | THE UNIVERSITY OF UTAH | 2015-02-05 | — | — | US | disclosed |
| US-5128408-A | Quaternized amino polyurethane- or polyurethaneurea-polysiloxanes treated with heparin | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1992-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038512-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | SRM, SMOX, SMS | CYP1A2 4330/4885MAPK1 3755/4885CHRM2 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.